Counsel Washington, D.C.
`
`+1 202 682 7024
`
`
`
`robert.vlasis@weil.com
`
`Practice Areas
`
`Patent Litigation
`
`Admissions
`
`District of Columbia
`Eastern District Texas
`US Ct App Federal Circuit
`Northern District Texas
`State of Texas
`US Supreme Court
`
`Education
`
`Baylor University (B.B.A., 2000)
`University of Houston Law Center (J.D., 2006)
`
`Robert T. Vlasis III is counsel in Weil’s Patent Litigation group and is
`an expert in Section 337 investigations before the U.S. International
`Trade Commission. He has 15 years of experience representing
`innovator companies such as Regeneron, Johnson & Johnson,
`General Electric, Microsoft, Illumina, and Under Armour before all of
`the major patent law venues in high-stakes IP disputes involving an
`array of technologies.
`Robert has counseled clients in more than two dozen ITC investigations, has taken or
`defended over 100 depositions, and has second-chaired a dozen bench and jury trials. He
`consistently plays a lead role in all phases of complex, multi‑party, multi-jurisdictional patent
`litigations, from pre-suit investigation, to case management and strategy, witness
`presentation and cross-examination at trial, oral argument, mediation and settlement, and
`briefing on appeal. He has experience with a wide variety of complex technologies relating to
`life sciences, pharmaceuticals, cellular and wireless communications, smartphones and
`tablets, medical devices, and wearable devices and fitness.
`
`Some of Robert’s representative ITC experience includes:
`
`Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207
`represented respondent Regeneron and developed an extensive record on the statutory public
`interest factors
`Novartis withdrew its complaint and terminated the investigation following the rare finding by the
`Office of Unfair Import Investigations (OUII) that the public interest record supported no relief even
`if a Section 337 violation were found
`Certain Laparoscopic Surgical Staplers, Reload Cartridges, and Components Thereof, Inv. No. 337-
`TA-1167
`represented complainant Ethicon (a Johnson & Johnson subsidiary)
`obtained Commission finding of a violation of Section 337 by Intuitive Surgical
`Certain Variable Speed Wind Turbine Generators and Components Thereof, Inv. No. 337-TA-1218
`represented complainant General Electric
`obtained final initial determination of a Section 337 violation by Siemens
`Certain IoT Devices and Components Thereof, Inv. No. 337-TA-1094
`obtained termination of investigation on an early motion to dismiss
`Certain RF Capable Integrated Circuits and Products Containing the Same, Inv. No. 337-TA-982
`complainant withdrew its complaint following favorable motion in limine ruling
`Certain Wireless Communication Devices, Portable Music and Data Processing Devices, Computers
`and Components Thereof, Inv. No. 337-TA-745
`obtained no violation finding on all six asserted patents
`Certain Electronic Devices with Multi-Touch Enabled Touchpads and Touchscreens, Inv. No. 337-TA-
`714
`obtained no violation finding on single asserted patent
`Certain Mobile Telephones and Wireless Communication Devices Featuring Digital Cameras, and
`Components Thereof, Inv. No. 337-TA-703
`obtained no violation finding on single asserted patent
`Certain Semiconductor Chips with Minimized Chip Package Size and Products Containing Same, Inv.
`No. 337-TA-649
`represented respondents ASE and STATS ChipPAC against complainant Tessera
`complainant withdrew complaint following exchange of expert reports
`Recent district court wins include:
`
`Verinata Health, Inc. v. Ariosa Diagnostics, Inc., Case No. 3:12-cv-05501-SI (N.D. Cal.)
`obtained $27 million jury verdict and dismissal of $100 million counterclaims on patents directed to
`prenatal testing for the early diagnosis of fetal abnormalities such as Down’s Syndrome
`affirmed by the Federal Circuit
`Bio-Rad Laboratories, Inc. v. 10X Genomics Inc., Case No. 1:15-cv-00152-RGA (D. Del.)
`
`Regeneron Exhibit 1099.001
`Regeneron v. Novartis
`IPR2021-00816
`
`Robert T. Vlasis
`Printed: January 21, 2022
`

`

`obtained $24 million jury verdict and permanent injunction on patents directed to foundational
`technology that allows thousands of microscopic “droplets” to serve as test tubes for chemical
`reactions with genetic material
`affirmed by the Federal Circuit
`Robert also contributes extensively to Weil’s diversity efforts and with recruiting, training, and
`mentoring. He is also dedicated to pro bono matters and defending the rights of LGBTQ+
`people and people with HIV. He co-authored an amicus brief in Obergefell v. Hodges, the
`landmark Supreme Court case that legalized same-sex marriage, and another Supreme
`Court amicus brief concerning discriminatory transgender bathroom laws. His representation
`of immigrant clients fighting deportation as a result of the now-repealed HIV travel and
`immigration ban was featured in multiple, international media outlets including the Los
`Angeles Times and the BBC, among others. Robert has been recognized for his pro bono
`work, which earned Weil the HIV Law Project’s Distinguished Pro Bono Legal Service
`Award.
`
`Robert is a member of the ITC Trial Lawyers Association and the ITC section of the
`American Bar Association. His civic affiliations include service as past Chair of the
`Campaign Board’s Eastern Caucus for the Gay & Lesbian Victory Fund, and on the Levine
`School of Music Virtuoso Society Steering Committee. He is a member of the Human Rights
`Campaign Federal Club, a past member of the Lambda Legal Liberty Circle, and a past
`chairman of the Milby High School Leadership 2000 Mentoring Program.
`
`Firm News & Announcements
`
`Weil Delivers Dual Federal Circuit Wins for Bio-Rad and Illumina Protecting DNA Sequencing and Analysis
`Litigation Win — August 05, 2020
`
`Weil Wins Federal Circuit Victory Upholding $27M Patent Infringement Jury Verdict
`Litigation Win — April 24, 2020
`
`Copyright © 2022 Weil, Gotshal & Manges LLP, All Rights Reserved. The contents of this website may contain attorney advertising under the laws of
`various states. Prior results do not guarantee a similar outcome. Weil, Gotshal & Manges LLP is headquartered in New York and has office locations in
`Beijing, Boston, Dallas, Frankfurt, Hong Kong, Houston, London, Miami, Munich, New York, Paris, Princeton, Shanghai, Silicon Valley and Washington,
`D.C.
`
`Regeneron Exhibit 1099.002
`Regeneron v. Novartis
`IPR2021-00816
`
`